RxDoctor Payments Data

Syed Asad Shah, MD

Family Medicine · Worthington, MNNPI 1821319344

Payments from drug & device makers

$226in general payments, 2019–2025

Across 16 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$58
  • Sanofi-aventis U.S. LLC$26
  • Boehringer Ingelheim$21
  • Corcept Therapeutics$18
  • AstraZeneca$16
  • Medtronic$15
  • plus $73 from 6 others

What the payments were for

  • Food & beverage$226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$226 in reported general payments places this provider in the 80th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$8,957
Medicare patients
44
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$138,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$73,889
JanuviaSitagliptin Phosphate46$67,935
JardianceEmpagliflozin58$63,434
FarxigaDapagliflozin Propanediol32$51,853
TrulicityDulaglutide28$39,660
MounjaroTirzepatide24$34,892
SymbicortBudesonide/Formoterol Fumarate79$30,264
RybelsusSemaglutide23$29,396
EntrestoSacubitril/Valsartan17$26,447
BelsomraSuvorexant53$25,426
TradjentaLinagliptin21$22,677
EliquisApixaban14$18,702
MyrbetriqMirabegron21$18,118
XareltoRivaroxaban22$17,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$58$167,507107 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat$21$97,205102 claims
AstraZenecaFarxiga, Symbicort$16$82,116111 claims
Lilly USA, LLCTrulicity, Mounjaro$12$74,55252 claims
PfizerEliquis$12$18,70214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in Worthington

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →